natgillin/translations-raw huggingface dataset:
p-стойност (едностран- но)
P-value (one-sided)
p-стойност (експлораторна)
p-value (exploratory)
p-стойност (логаритмично преобразуван рангов тест)
p-value (log-rank test)
p-стойност (логаритмично преобразуван ренков тест)
p-value (log-rank test)
p-стойност (с кор. по Simes за CMH
p-value (with Simes corr. for CMH test)4
P-стойност (спрямо плацебо)
blood creatine phosphokinase increased, posture
P-стойност (спрямо,
P value (vs Placebo)
P-стойност (спрямо,
P-value (vs, Placebo)
P-стойност (спрямо,
P-value (vs.
p-стойност (тест на Cochran-Mantel- Haenszel)
p-value (Cochran-Mantel-Haenszel test)
p-стойност (хи квадрат тест на Mantel- Haenszel*)
p-value (Mantel-Haenszel chi-squared test*)
P-стойност (хи-квадрат тест)
P-value (chi-square test)
p-стойност 3
p-value 3
p-стойност 3, 4
p-value 3, 4
p-стойност c
p-valuec
P-стойност б, д
P-value b, e
p-стойност в Ден 29
Day 29 p-value
p-стойност за не по-малка ефикасностс
p-value for non-inferiorityc
p-стойност за неинфериорност (HR)
 Non-inferiority p-value (HR)
p-стойност за превъзходство
p-value for superiority
P-стойност за промяната от преди лечението [1]
P-value for change from pre-Tx [1]
p-стойност за стратифициран Log-rank тест*
Stratified Log-Rank Test p-value
p-стойност за стратифициран Log-rank тест**
Stratified Log-Rank Test p-value
p-стойност от CMH тест за честотата на отговор (спрямо иматиниб 400 mg еднократно дневно)
CMH test p-value for response rate (versus imatinib 400 mg once daily)
P-стойност от Cox регресионен модел, стратифициращ за място на заболяване и преди адювантна терапия при скрининг.
P-value from Cox regression model, stratifying for site of disease and prior anti-adjuvant therapy at screening.
P-стойност спрямо наблюдение
P-value versus Observation
p-стойност спрямо плацебо
p-value versus placebo
P-стойност спрямо плацебо2
P-value vs. placebo2
p-стойност съгласно точния тест на Fisher*
Fisher’s exact p-value
p-стойност ‡
p-value
p-стойност*
95% CI
p-стойност*
p- value
p-стойност*
p-value
p-стойност**
p-value
p-стойност+
p-value+
P-стойност, Логаритмично трансформиран ренков тест (Log-rank test)
P-value, Log-rank test
p-стойност, тест за превъзходство
p-value, test for superiority
p-стойност1
p-value1
p-стойност2
p-value2
p-стойност4
p-value4
p-стойност6
p-value6
p-стойностa
38.6 (549/1,423)
p-стойностa
p valuea
p-стойностa
p-valuea
p-стойност°
p-value°
p-стойноста
p value a
p-стойноста (двустранна)
p-valuea (2-sided)
p-стойностб
p-valueb
p-стойноств
p-valuec
p-стойностг
p-valued
p-стойносте
p-valuef
p-стойностж
p-valueg
p-стойностж=0,275
p-valueg=0.275
P-стойностите за URAI се отнасят до нулевата хипотеза, че ефикасността се различава между стрататите на подгрупата (URAI, без URAI). б Относително намаляване на риска, изчислено за mITT, базирано на настъпилата сероконверсия, т.е. възникнала след изходно ниво до първата визита след лечението (приблизително 1 месец след последното раздаване на проучваното лекарство).
P-values for URAI refer to the null hypothesis that efficacy differed between subgroup strata (URAI, no URAI). b Relative risk reduction calculated for mITT based on incident seroconversion, ie, occurring post-baseline through first post-treatment visit (approximately 1 month after last study drug dispensation).
P-стойностите за оланзапин и кветиапин XR спрямо плацебо не са били коригирани.
P-values for olanzapine and quetiapine XR vs. placebo were unadjusted.
P-стойностите за сравняване със стойностите преди лечението са изчислени чрез t-тестове по двойки.
[1] P-values for comparison versus pre-Tx values were computed using paired t-tests.
p-стойностите са < 0,001 както за mTSS, така и за ерозионния скор и ≤0,01 за JSN скор.
p-values were < 0.001 for both mTSS and erosion score and ≤ 0.01 for JSN score.
p-стойността е получена от log-rank тест, стратифициран по изходен ECOG скор (0 или 1)
p-value is derived from a log-rank test stratified by baseline ECOG score (0 or 1)
P-стойностя, б
P-valuea, b
p-стойност†
p-Value
p-стойност† *
p-value
p-стойност†*
p-value
P. 32
B.P. 32
P. aeruginosa и FEV1 ≤ 75% от предвидения са получили Cayston в клинични проучвания фаза 2 и фаза 3 (6-12 години, n=35; 13-17 години, n=102).
≤ 75% predicted have received Cayston in Phase 2 and Phase 3 clinical studies (6-12 years, n = 35; 13-17 years, n = 102).
P. aeruginosa и FEV1 ≤ 75% от предвидения са получили Cayston в клинични проучвания фаза 2 и фаза 3.
≤ 75% predicted have received Cayston in Phase 2 and Phase 3 clinical studies.
P. aeruginosa към момента и предшестващо лечение с аерозолни антибиотици без проява на лекарствена непоносимост.
P. aeruginosa, and previous treatment with aerosolised antibiotics without demonstration of drug intolerance.
P. aeruginosa, които са имали кистозна фиброза.
P. aeruginosa lung infection.
P./Tel: +358 (0)9 279 80 80
P. /Tel: +358 (0)9 279 80 80
p.?(Екзон1_2del)
p.?(Exon1_2del)
P.O. Box 1117 SE-221 04 Lund Швеция
P.O. Box 1117 SE-221 04 Lund Sweden
P.O. BOX 4220 Nydalen NO-0401 OSLO, Норвегия
P.O.BOX 4220 Nydalen NO-0401 OSLO, Norway
P.O.BOX 4220 Nydalen NO-0401 Oslo, Норвегия
P.O.BOX 4220 Nydalen NO-0401 Oslo, Norway
p/a Trust Company Amsterdam B.V.
p/a Trust Company Amsterdam B.V. Crystal Tower 21st Floor,
P/P-gp от
Cmax
P0,5/R Рибавирин (1 000/1 200 mg) + ПЕГ-интерферон алфа-2b (1,5, след което 0,5 микрограма/kg) I/R Рибавирин (1 000/1 200 mg) + интерферон алфа-2b (3 MIU)
P0.5/R Ribavirin (1,000/1,200 mg) + peginterferon alfa-2b (1.5 to 0.5 microgram/kg) I/R Ribavirin (1,000/1,200 mg) + interferon alfa-2b (3 MIU)
P1 Програма 1: 5 микрограма активно вещество при мундщука, 25 инхалаторни цикъла.
P1 Programme 1: 5 microgram active substance on the mouth piece 25 inhalation cycles.
P1 Програма 1: 5,0 микрограма активно вещество при мундщука, 25 инхалаторни цикъла.
P1 Programme 1: 5 microgram active substance on the mouth piece 25 inhalation cycles.
P1,5/R Рибавирин (800 mg) + ПЕГ-интерферон алфа-2b (1,5 микрограма/kg)
P1.5/R Ribavirin (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg)
P1,5/R Рибавирин (800 mg) + пегинтерферон алфа-2b (1,5 micrograms/kg)
P1.5/R Ribavirin (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg)
P1,5/R Рибавирин (800 mg)+ПЕГ-интерферон алфа-2b (1,5 micrograms/kg)
P1.5/R Ribavirin (800 mg) + peginterferon alfa-2b (1.5 micrograms/kg)
P1A[8] 2,3 x 106 инфекциозни единици
P1A[8] 2.3 x 106 Infectious Units
P1A[8]  2,3 х 106 IU1
P1A[8]  2.3 x 106 IU1
p< 0,00003*
p< 0.00003
p< 0,0001
p< 0.0001
p< 0,0001*
p< 0.0001
p< 0,001
p<0.001
p< 0,007*
p< 0.007
p< 0,035
p< 0.035
p<0,0001
10.5
P<0,0001
4051
p<0,0001
p<0.0001
P<0,0001 HR (95%CI):
P< HR ( 0.798 (0
p<0,001
p<0.001
P<0,001 в полза на такролимус маз 0,1% (за възрастни) и 0,03% (за деца) за първичната и ключовите вторични крайни точки.
P<0.001 in favour of tacrolimus ointment 0.1% (adults) and 0.03% (children) for the primary and key secondary endpoints
p<0,05, **p<0,01, ***p<0,001 Клинични проучвания при деменция, свързана с болестта на Паркинсон
Clinical studies in dementia associated with Parkinson’s disease
p= 0,0131
p= 0.0131
p= 0,0341
p=0.0341
p=0,000 4
p=0.0004
P=0,0000
P=0.0000
P=0,0001
P=0.0001
p=0,0003
26.6
p=0,0003
p=0.0003
P=0,0006
P=0.0006
p=0,0008
p=0.0008
P=0,001
P=0.001
p=0,0011
p=0.0011
P=0,0014
P=0.0014
p=0,002
p=0.002
p=0,0021
p=0.0021
p=0,003
p<0.0001 p=0.003
p=0,003
p=0.003
p=0,0035Е)
(7.1, 14.0) p<0.0001
p=0,0037
p=0.0037
p=0,004
p=0.004
p=0,007
p=0.007
p=0,007 0
p=0.0070
p=0,008
p=0.008
p=0,0084
p=0.0084
P=0,01
P=0.01
p=0,0100
p=0.0100
P=0,0101
P=0.0101
p=0,0124
p=0.0124
P=0,0140
P=0.0140
P=0,0172
P=0.0172
p=0,018
p=0.018
p=0,019
p=0.019
p=0,0197
p=0.0197
p=0,0211
p=0.0211
p=0,025
p=0.025
p=0,026
p=0.026
p=0,0296
(13.0, 40.1) p=0.0003
p=0,03
p=0.03
p=0,032
p=0.032
P=0,0385
P=0.0385
p=0,041
p=0.041
p=0,0555
p=0.0555
p=0,0707
p=0.0707
P=0,080
p=0.080
p=0,083
p=0.083
p=0,0871
p=0.0871
p=0,1087
p=0.1087
P=0,12
P=0.12
P=0,1380
P=0.1380
p=0,16
p=0.16
p=0,177
p=0.177
P=0,191
p=0.191
p=0,1983
p=0.1983
p=0,2420
p=0.2420
p=0,2942
p=0.2942
P=0,30
P=0.30
p=0,4170
p=0.4170
p=0,4449
p=0.4449
P=0,45
P=0.45
P=0,48
P=0.48
p=0,536
p=0.536
p=0,5771
p=0.5771
P=0,7134
P=0.7134
p=0,7382
p=0.7382
P=0,76
P=0.76
P>0,05‡
P>0.05
PA 19428 САЩ
United States
PA/Al/PVC – Al блистери:
PA/Alu/PVC – Alu blisters:
PA/Al/PVC – Al перфориран еднодозов блистер
PA/Alu/PVC – Alu perforated unit-dose blister
PA/Alu/PVC - Alu блистер, съдържащ 10 твърди капсули.
PA/Alu/PVC - Alu blister containing 10 hard capsules
PA/Alu/PVC блистери
PA/Alu/PVC blisters
PA/Alu/PVC блистери:
PA/Alu/PVC – Alu blisters:
PA/Alu/PVC – Alu блистери:
PA/Alu/PVC – Alu blisters:
PA/Alu/PVC – Alu блистери: 18 месеца
PA/Alu/PVC – Alu blisters: 18 months
PA/Alu/PVC – Alu календарни блистери: 18 месеца
PA/Alu/PVC – Alu calendar blisters: 18 months
PA/Alu/PVC – Alu перфориран еднодозов блистер.
PA/Alu/PVC – Alu perforated unit-dose blister.
PA/Alu/PVC/Alu 2 години
PA/Alu/PVC/Alu 2 years
PA/aлуминий/PVC/алуминиеви блистери, опаковки от 14, 28, 30, 50, 56, 90 и 98 таблетки..
PA/Aluminium/PVC/Aluminium blisters, packs of 14, 28, 30, 50, 56, 90 and 98 tablets.
pA/pT (95,1 % ДИ)
pA/pT (95.1% CI)
Pa3npe)],eJleHHe
Distribution
Pabianice Полша
95-200 Pabianice Poland
Pacienti byli randomizováni v poměru 1:1, aby dostávali buď 300 mg atazanaviru se 150 mg kobicistatu jednou denně, nebo 300 mg atazanaviru se 100 mg ritonaviru jednou denně, a každé skupině byla podávána fixní výchozí léčba obsahující 300 mg tenofovir-disoproxyl-fumarátu a 200 mg emtricitabinu ve formě kombinované tablety s fixními dávkami.
Patients were randomised in a 1:1 ratio to receive either atazanavir 300 mg with cobicistat 150 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, each administered with a fixed background regimen containing tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg administered as a fixed-dose combination tablet.
Pacienti byli sledováni 30 dní.
The patients were followed for 30 days.
Pacienti mají být informováni o tom, že v průběhu léčby, jejíž součástí je atazanavir nebo kobicistat, byly hlášeny závratě (viz bod 4.8).
However, patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir or cobicistat (see section 4.8).
Pacienti mají být poučeni, aby vyhledali lékařskou pomoc, pokud zaznamenají bolesti kloubů, ztuhlost kloubů nebo pokud mají pohybové potíže.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Pacienti mají být seznámeni s těmito známkami a příznaky a kožní reakce musí být pečlivě sledovány.
Patients should be advised of the signs and symptoms and monitored closely for skin reactions.
Pacienti s hemofilií
Haemophiliac patients
Pacienti s koinfekcí virem chronické hepatitidy B či hepatitidy C
Patients with chronic hepatitis B or hepatitis C virus co-infection:
Pacienti s lehkou poruchou funkce jater (třída A podle Child-Pugha) mají atazanavir užívat s opatrností.
Atazanavir should be used with caution in patients with mild (Child-Pugh Class A) hepatic impairment.
Pacienti s lehkou poruchou funkce jater mají přípravek EVOTAZ užívat s opatrností (viz body 4.2, 4.3 a 5.2).
EVOTAZ should be used with caution in patients with mild hepatic impairment (see sections 4.2, 4.3 and 5.2).
Pacienti s lehkou poruchou funkce jater mají přípravek EVOTAZ užívat s opatrností.
EVOTAZ should be used with caution in patients with mild hepatic impairment.
Pacienti s odpovědí
Responders
Pacienti s ooruchou funkce jater a ledvin
Hepatic and renal impairment
Pacienti s poruchou funkce jater a ledvin
Hepatic and renal impairment
Pacienti se středně těžkou až těžkou poruchou funkce jater přípravek EVOTAZ nesmí užívat (viz bod 4.3).
EVOTAZ must not be used in patients with moderate to severe hepatic impairment (see section 4.3).
Pacienti se vzácnými dědičnými problémy s intolerancí galaktos, nedostatkem laktas nebo malabsorpcí glukóos a galaktosy by tento přípravek neměli užívat.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Pacienti so zvýšeným AST, ALT a alkalickou fosfatázou medzi cyklami si môžu vynútiť zníženie dávky (pozri časť 4.2).
Patients with increases in AST, ALT and alkaline phosphatase between cycles may necessitate dose reduction (see section 4.2).
Pacienti současně infikovaní virem hepatitidy B a/nebo hepatitidy C
Patients co-infected with hepatitis B and/or hepatitis C virus
Pacienti, kteří amiodaron užívají, by se měli před začátkem léčby alli poradit s lékařem.
Patients who are taking amiodarone should consult a doctor before starting treatment with alli.
Pacienti, kteří užívají amiodaron, by se před začátkem léčby alli měli poradit s lékařem (viz bod 4.5).
Patients who are taking amiodarone should consult a doctor before starting treatment with alli (see section 4.5).
Pacienti, u ktorých sa prejaví horúčka, musia okamžite vyhľadať lekársku pomoc.
Patients who develop fever should promptly seek medical attention.
Pacienti, u nichž v průběhu léčby ADHD vyvstanou sebevražedné představy nebo chování, musí být okamžitě vyšetřeni lékařem.
Patients with emergent suicidal ideation or behaviour during treatment for ADHD should be evaluated immediately by their physician.
Pacienti/ošetřovatelé mají být poučeni, aby bez konzultace s ošetřujícím lékařem podávání guanfacinu neukončovali.
Patients/caregivers should be instructed not to discontinue guanfacine without consulting their physician.
Pacientky nemají kojit, pokud užívají EVOTAZ.
Patients should not breast-feed while taking EVOTAZ.
Pacienty je třeba na tyto možné
Patients should be warned about
Pacienty je třeba upozornit na tyto možné účinky a poučit je, že při jejich výskytu se musejí uvedených činností vyvarovat (viz bod 4.4).
Patients should be warned of these possible effects and be advised that if affected, they should avoid these activities (see section 4.4).
Pacienty je třeba upozornit, aby dodržovali doporučená dietetické opatření (viz bod 4.2).
Patients should be advised to adhere to the dietary recommendations they are given (see section 4.2).
Pacienty je třeba upozornit, že mohou nastat somnolence a sedace, zvláště na počátku léčby nebo při navýšení dávky.
Patients should be advised that somnolence and sedation can occur, particularly early in treatment or with dose increases.
pacientů s akutním infarktem myokardu s ST elevací byla bezpečnost a účinnost klopidogrelu hodnocena ve 2 randomizovaných, placebem kontrolovaných, dvojitě zaslepených studiích, CLARITY a COMMIT.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
pacientů s akutním infarktem myokardu s ST elevací byla bezpečnost a účinnost klopidogrelu ověřena ve 2 randomizovaných, placebem kontrolovaných, dvojitě zaslepených studiích, CLARITY a COMMIT.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
Pacientům se doporučuje pít hodně tekutin.
Patients should be advised to drink plenty of fluid.
Pacira Limited, Wessex House, Marlow Road, Bourne End, Buckinghamshire, SL8 5SP, Обединено кралство
Pacira Limited, Wessex House, Marlow Road, Bourne End, Buckinghamshire, SL8 5SP, United Kingdom.
PAES: За да определи допълнително ефикасността на олапариб при пациенти с чувствителен на платина рецидивирал високостепенен серозен рак на яйчниците със соматична BRCA мутация, ПРУ трябва да проведе и подаде резултатите от отворено, нерандомизирано, многоцентрово проучване с едно рамо фаза IV при пациенти с чувствителен на платина рецидивирал рак на яйчниците, които са с пълен или частичен отговор след базирана на платина химиотерапия и които са носители на загуба на функция на герминативна линия и/или соматична BRCA мутация(ии).
PAES: In order to further define the efficacy of olaparib in patients with platinum sensitive relapsed somatic BRCA mutated high grade serous ovarian cancer, the MAH should conduct and submit the results of a phase IV, open label, single arm, non- randomised, multicentre study in patients with relapsed platinum sensitive ovarian cancer who are in complete or partial response following platinum based chemotherapy and who carry loss of function germline or somatic BRCA mutation(s).
PAES: За да се определи допълнително дългосрочната ефикасност на олапариб при пациентки с чувствителен на платина рецидивирал високостепенен серозен рак на яйчниците с BRCA мутация, ПРУ трябва да подаде крайния анализ на общата преживяемост (ОП) от проучване D0810C00019, рандомизирано двойносляпо, многоцентрово проучване фаза II.
PAES: In order to further define the long term efficacy of olaparib in patients with platinum sensitive relapsed BRCA mutated high grade serous ovarian cancer, the MAH should submit the final Overall Survival (OS) analysis of study D0810C00019, a phase II randomised, double blind, multicentre study.
Page 1/1
1/1
Paglitaz 15 mg таблетки Пиоглитазон
Paglitaz 15 mg tablets Pioglitazone
Paglitaz 30 mg таблетки Пиоглитазон
Paglitaz 30 mg tablets Pioglitazone
Paglitaz 45 mg таблетки Пиоглитазон
Paglitaz 45 mg tablets Pioglitazone
Paglitaz е „генерично лекарство“.
Paglitaz is a ‘generic medicine’.
Paglitaz може да се използва в комбинация с метформин при пациенти, чието състояние не се контролира задоволително с метформин самостоятелно или сулфонилурейно производно (друг вид лекарство срещу диабет), когато метформин не е подходящ (двойна терапия).
Paglitaz can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetes medicine) when metformin is not suitable (‘dual therapy’).
Paglitaz може да се използва също в комбинация с метформин и сулфонилурейно производно при пациенти с незадоволителен контрол на болестта въпреки двойната терапия през устата (тройна терапия).
Paglitaz can also be used together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy by mouth (‘triple therapy’).
Paglitaz пиоглитазон
Paglitaz pioglitazone
Paglitaz с храна, напитки и алкохол
Paglitaz with food and drink
Paglitaz се използва за лечение на диабет тип 2 при възрастни (на 18 и повече години), по- специално при възрастни с наднормено тегло.
Paglitaz is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
PAKENDI INFOLEHT
PACKAGE LEAFLET
Pakendi infoleht: informatsioon kasutajale
Keep this leaflet.
Pakendi iseloomustus ja sisu
Nature and contents of container
PAKENDI MÄRGISTUS
LABELLING
PAKENDI MÄRGISTUS JA INFOLEHT
LABELLING AND PACKAGE LEAFLET
Pakendi sisu ja muu teave
Contents of the pack and other information
Pakendi sisu ja muu teave Mida Mycamine sisaldab
Contents of the pack and other information What Mycamine contains
PAKENDI SISU KAALU, MAHU VÕI ÜHIKUTE JÄRGI
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
Pakendis 1 viaal.
Supplied in packs of 1 vial.
Pakirana je v kartonsko škatlico z 1 ml stekleno napolnjeno injekcijsko brizgo z 1 odmerkom.
It is supplied as a carton pack containing 1 single-dose, glass 1 mL pre-filled syringe.
Pakirana je v kartonsko škatlico z 2 ml stekleno vialo z 1 odmerkom.
It is supplied as a carton pack containing 1 single-dose, glass 2 mL vial.
Pakiranja:
Packaging:
Pakiranje z 1 vialo.
Pack of 1 vial.
Pakirano je v kartonsko škatlico s 30 ml stekleno vialo z 1 odmerkom.
It is supplied as a carton pack containing 1 single-dose, glass 30 mL vial.
PAKNINGSSTØRRELSE ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
PAKNINGSSTØRRELSE ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER
CONTENTS BY WEIGHT, BY VOLUME OR BYNUMBER OF DOSES
PAKNINGSSTØRRELSE ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER
CONTENTS BY WEIGHT, BY VOLUME OR NUMBER OF DOSES
Pakningsstørrelser er på 30 eller 100 tabletter.
Pack sizes are of 30 or 100 tablets.
Palackého trída 163a 612 00 Brno
Palackého trída 163a 612 00 Brno CZECH REPUBLIC
palavik vappekülmad (külmavärinad)
fever rigors (shivering)
palavik, külmavärinad
Investigations
Palladia
EU/2/09/100/002
Palladia
EU/2/09/100/003
Palladia 10 mg филмирани таблетки за кучета Palladia 15 mg филмирани таблетки за кучета Palladia 50 mg филмирани таблетки за кучета
Palladia 10 mg film-coated tablets for Dogs Palladia 15 mg film-coated tablets for Dogs Palladia 50 mg film-coated tablets for Dogs
Palladia таблетки трябва да бъдат приложени на Вашето куче незабавно след изваждане от блистера.
Palladia tablets should be given to your dog immediately after they are removed from the blister and should not be left around where they could be handled/swallowed by children.
Pallagi út 13 Унгария
Pallagi út 13 Hungary
Pallagi út 13, Унгария
Pallagi út 13, Hungary
Pallini 15351 Attiki Гърция
Pallini 15351 Attiki Greece
Pallini 15351 Attiki, Гърция
Pallini 15351 Attiki, Greece
Pallini 15351, Attiki Гърция
Pallini 15351, Attiki Greece
Pallini 15351, Attiki, Гърция Tel.: +30 210 66 04 300
Pallini 15351, Attiki, Greece Tel.: +30 210 66 04 300
Pallini Attiki, 15351 Гърция
Pallini Attiki, 15351 Greece
Palonosetron 250 mikrogramov (n = 185)
Palonosetron 250 micrograms (n= 185)
Palonosetron 250 mikrogramov (n = 189)
Palonosetron 250 micrograms (n= 189)
Palonosetron 250 mikrogramov (n = 223)
Palonosetron 250 micrograms (n= 223)
Palonosetron Accord е „генерично лекарство“.
It is a ‘generic medicine’.
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje
Palonosetron Hospira250 micrograms solution for injection.
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje palonosetron
Palonosetron Hospira 250 micrograms solution for injection palonosetron
Palonosetron Hospira 250 mikrogramov raztopina za injiciranje palonosetron (v obliki palonosetronijevega klorida)
Palonosetron Hospira 250 micrograms solution for injection palonosetron (as hydrochloride)
Palonosetron je bil v akutni fazi bruhanja enako učinkovit, tako pri zmerno kot visoko emetogeni kemoterapiji, kot primerjana zdravila.
Palonosetron was non-inferior versus the comparators in the acute phase of emesis both in moderately and highly emetogenic setting.
Palonosetron je varen pri sočasnem jemanju z analgetiki, antiemetiki/zdravili proti slabosti, spazmolitiki in antiholinergiki.
Palonosetron has been administered safely with analgesics, antiemetic/antinauseants, antispasmodics and anticholinergic medicinal products.
Palonosetron je varen pri sočasni uporabi s kortikosteroidi.
Palonosetron has been administered safely with corticosteroids.
Palonosetron ni mutagen.
Palonosetron is not mutagenic.
Palonosetron pri klinično pomembnih koncentracijah ne inhibira ali inducira citokrom P450 izoencimov.
Palonosetron does not inhibit or induce cytochrome P450 isoenzymes at clinically relevant concentrations.
Palonosetron večinoma metabolizira encim CYP2D6, nekaj pa tudi izoencima CYP3A4 in CYP1A2.
Palonosetron is mainly metabolised by CYP2D6, with minor contribution by CYP3A4 and CYP1A2 isoenzymes.
palpitacije
Palpitations
Palun öelge oma arstile, kui teil on olnud raskeid maksaprobleeme (nt maksapuudulikkust või maksapõletikku (hepatiiti)) või teil on esinenud maksafunktsiooni testide kõrvalekallet normist.
Please tell your doctor if you have severe liver problems (e.g. liver failure or hepatitis) or have had abnormal liver function tests.
Pamatujte
Remember
Pamidronat 90 mg (N=99)
Pamidronate 90 mg (N=99)
Panacur AquaSol 200 mg/ml, суспензия за приложение във водата за пиене, за прасета и пилета.
Panacur AquaSol 200 mg/ml suspension for use in drinking water for pigs and chickens
Panacur AquaSol e лекарство, съдържащо активната субстанция фенбендазол (fenbendazole).
Panacur AquaSol is a medicine that contains the active substance fenbendazole.
Panacur AquaSol е изпитан в три основни проучвания при пасета.
Panacur AquaSol was tested in three field studies involving pigs.
Panacur AquaSol не бива да бъде изхвърлян във водни басейни, тъй като това може да бъде опасно за риби и други водните организми.
Panacur Aquasol should not enter water courses as this may be dangerous for fish and other aquatic organisms.